Why the study?
Case reports of myocarditis after COVID-19 mRNA vaccination have not uniformly reported long-term follow-up beyond 90 days.
Post-mRNA vaccine myocarditis typically presents with a mild, self-limiting course that can be diagnosed clinically and with imaging, without the routine need for endomyocardial biopsy.
Answers are grounded in this paper and cite their sources.
Supports favorable long-term outcomes in typical post-mRNA vaccine myocarditis; leaves open need for systematic prospective follow-up beyond 90 days.
Case reports of myocarditis post-coronavirus disease 2019 (COVID-19) mRNA vaccination have not uniformly reported long-term follow-up beyond 90 days. We present a 23-year-old male who is typical of a patient presenting with myocarditis post-COVID-19 mRNA-1273 Moderna vaccination (young males, onset several days after second dose of the mRNA vaccine, and excellent short term complete recovery). Follow-up at 128 days revealed no residual sequelae in our patient. Although a definitive diagnosis of myocarditis requires an endomyocardial biopsy (EMB), diagnosis is usually made clinically and with imaging in most clinical settings unless part of an approved research protocol or if indicated clinically. We recommend active surveillance and reporting for myocarditis post mRNA vaccination and even consider reporting those with symptom onset beyond 90 days.
No takes yet. Share an insight, caveat, or question.
McCullough et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: